The Emergence of Omicron SARS-CoV-2 Variant (B.1.1.529): The Latest
Episode in the COVID-19 Pandemic with a Global Riposte

Suman   Kumar   Ray; Sukhes      Mukherjee

Abstract

Over two years after the start of the SARS-CoV-2 epidemic, which has demised over 5 million people, the world is still on high COVID-19 alert in February 2022, and new variants are emerging. Since January 2020, the World Health Organization (WHO) has been closely monitoring and analyzing the evolution of SARS-CoV-2 in partnership with national authorities, public health organizations, and scientists. To prioritize global monitoring and research and to guide the continuing global response to the COVID-19 pandemic, distinct SARS-CoV-2 variants were labelled as Variant of Interest (VOI) and Variant of Concern (VOC). The World Health Organization and its international sequencing networks are constantly monitoring SARS-CoV-2 mutations and informing countries about any adjustments that may be required to respond to the variant and, where possible, prevent its spread. Since January 2021, multiple viral variations have evolved and grown dominant in numerous countries, with the Alpha, Beta, Gamma, and Delta varieties being the most prevalent too far. On November 20, 2021, Omicron was born into a COVID-19-weary world, replete with rage and resentment at the pandemic's broad detrimental effects on social, emotional, and economic well-being. Although earlier VOCs originated in a world where natural immunity to COVID-19 infections was widespread, the fifth VOC, Omicron, has emerged in an environment where vaccine immunity is rising.

Keywords: Omicron, variant of concern, SARS-CoV-2, pandemic, vaccine, global riposte, WHO.

Graphical Abstract

[1]
Fontanet A, Autran B, Lina B, Kieny MP, Karim SSA, Sridhar D. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet  2021; 397(10278): 952-4.
 [http://dx.doi.org/10.1016/S0140-6736(21)00370-6] [PMID: 33581803]

[2]
van Kampen JJA, van de Vijver DAMC, Fraaij PLA, et al. Duration and key determinants of infectious virus shedding in hospitalized pa-tients with coronavirus disease-2019 (COVID-19). Nat Commun  2021; 12(1): 267.
 [http://dx.doi.org/10.1038/s41467-020-20568-4] [PMID: 33431879]

[3]
Ray SK, Mukherjee S. COVID-19-Associated mucormycosis, A new incident in recent time: Is an emerging disease in the near future im-pending? Avicenna J Med  2021; 11(4): 210-6.
 [http://dx.doi.org/10.1055/s-0041-1735383] [PMID: 34881204]

[4]
Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: A data linkage study. Lancet  2022; 399(10323): 437-46.
 [http://dx.doi.org/10.1016/S0140-6736(22)00017-4] [PMID: 35065011]

[5]
 GISAID Initiative. COVID-19 lineages and variants. Munich: GISAID; 2021. 2021. Available from: www.gisaid.org

[6]
GitHub B.1.1. decendant associated with Southern Africa with high number of Spike mutations #343 2021. Available from 2021. 2021 https://github.com/cov-lineages/pango-designation/issues/343

[7]
 eNews Channel Africa (eNCA). Health Department briefs media about a new so-called super-variant. 2021. Available from: https://youtu.be/b4aTIoZDQk4

[8]
 World health organization (WHO). Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. 2021. Available from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern

[9]
 European centre for disease prevention and control (ECDC). Threat assessment brief: Implications of the emergence and spread of the SARS-CoV-2 B.1.1. 529 variant of concern (Omicron) for the EU/EEA. 2021. Available from: https://www.ecdc.europa.eu/en/publications-data/threat-assessment-brief-emergence-sars-cov-2-variantb. 1.1.529

[10]
Cele S, Jackson L, Khoury DS, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv  2021; 2021.12.08.21267417.
 [http://dx.doi.org/10.1101/2021.12.08.21267417]

[11]
Ray SK, Mukherjee S. Understanding the role of corona virus based on current scientific evidence - A review with emerging importance in pandemic. Recent Patents Anti-Infect Drug Disc  2020; 15(2): 89-103.
 [http://dx.doi.org/10.2174/1574891X15999200918144833] [PMID: 32957894]

[12]
 Threat assessment brief: Implications of the further emergence and spread of the SARS CoV 2 B.1.1.529 variant of concern (Omicron) for the EU/EEA first update. Available from: https://www.ecdc. europa.eu/en/publications-data/covid-19-threat-assessment-spread-omicron-first-update

[13]
 Österreichischer Rundfunk (ORF). Vier Omikron-Verdachtsfälle in Wien. ORF. 1 December 2021. 2021. Available from: https://wien. orf.at/stories/3132566/

[14]
Ziekenhuis U.  (UZ) Leuven Genomic surveillance of SARS-CoV-2 in Belgium. Leuven: UZ Leuven 2021. Available from: https://www.uzleuven.be/nl/laboratoriumgeneeskunde/genomic-surveillance-sars-cov-2-belgium

[15]
 Cable News Network (CNN). Italy confirms 5 new Omicron variant cases. CNN. 30 November 2021. 2021. Available from: https://edition.cnn.com/world/live-news/omicron-covid-19-variant- 11-30-21/h_27bb64211148071564272335f2af983f

[16]
 Statens Serum Institut (SSI). Status på omikron-varianten (B.1.1.529) pr. 30.11.21. 2021. Available from: https://www.ssi.dk/aktuelt/ nyheder/2021/status-om-omikron-varianten-b11529-pr-301121

[17]
 Bayerische landesamt für gesundheit und lebensmittelsicherheit (lgl). vierter fall der omikron-variante des SARS-CoV-2 in Bayern mittels Genomsequenzierung bestätigt. 2021. Available from: https://www. lgl.bayern.de/presse/pressemitteilungen/detailansicht.htm?ID=A%2Bs3RgSTi2Tz%2BAoEEso32g%3D%3D

[18]
Coffey D. Omicron variant found on French territory of Réunion RFI   2021. Available from:https://www.rfi.fr/en/france/20211130-omicron-variant-found-on-french-territory-of-r%C3%A9union

[19]
Department of Health - Government of Ireland. Statement from the national public health emergency team on the detection of omicron vari-ant in ireland .  2021 Available from: 

https://www.gov.ie/en/pressrelease/eab5d-statement-from-the-national-public-health-emergencyteam/

[20]
Jansen L, Tegomoh B, Lange K, et al. Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster - Nebraska, November-December 2021. MMWR Morb Mortal Wkly Rep  2021; 70(5152): 1782-4.

[21]
Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med  2022; 28(5): 1063-71.

[22]
Guo Y, Han J, Zhang Y, et al. He J, Yu W, Zhang X, Wu J, Zhang S, Kong Y, Guo Y, Lin Y, Zhang J. SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance. Front Immunol  2022; 13: 877101.

[23]
Pires D, de Sousa G. Doctor from B SAD and Garcia de Orta infected with Ómicron puts 56 people in isolation TSF Radio News.  2021 Available from:https://www.tsf.pt/portugal/sociedade/caso-de-omicron-no-hospital-garcia-de-orta-14368727.html

[24]
Zeitung B. Corona-Variante Omikron in Sachsen nachgewiesen Bild.  2021 Available from:https://www.bild.de/regional/leipzig/leipzig-news/omikron-leipziger-patient-39-hat-corona-variante-78392238.bild.html

[25]
Wong SC, Au AK, Chen H, et al. Transmission of Omicron (B.1.1.529) - SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19. Lancet Reg Health West Pac  2022; 18: 100360.

[26]
Demony C, Khalip A. Portugal finds 13 cases of Omicron variant at Lisbon soccer club Reuters.  2021 Available from:https://www. reuters.com/business/healthcare-pharmaceuticals/portugal-detects-13-cases-omicron-covid-19-variant-2021-11-29/

[27]
Staff TOI.  Two doctors infected with Omicron COVID variant; confirmed cases in Israel rise to 4. Times Isr 2021; 30 Available from: https://www.timesofisrael.com/2-doctors-infected-with-omicroncovid- variant-confirmed-cases-in-israel-hit-4/

[28]
Niblock J. Covid-19 Omicron variant case linked to Brentwood primary school.  2021 Available from:https://www.bbc.com/news/uk-england-essex-59458933

[29]
Maishman E. Omicron variant: Nine cases linked to single event as Scotland ramps up testing.  2021 Available from:https://www. scotsman.com/health/omicron-variant-nine-cases-linked-to-single-event-as-scotland-ramps-up-testing-3476969

[30]
 UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England: technical briefing 29. 2021. Available from: https://assets.publishing.service.gov.uk/government/ uploads/system/uploads/attachment_data/file/1036324/Technical_ Briefing_29_published_26_November_2021.pdf

[31]
Tao K, Tzou PL, Nouhin J, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet  2021; 22(12): 757-73.
 [http://dx.doi.org/10.1038/s41576-021-00408-x] [PMID: 34535792]

[32]
Gong SY, Chatterjee D, Richard J, et al. Contribution of single mutations to selected SARS-CoV-2 emerging variants Spike antigenicity. bioRxiv 455140.2021.

[33]
Wu H, Xing N, Meng K, et al. Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2. Cell Host Microbe  2021; 29(12): 1788-1801.e6.
 [http://dx.doi.org/10.1016/j.chom.2021.11.005] [PMID: 34822776]

[34]
Zahradník J, Marciano S, Shemesh M, et al. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolu-tion. Nat Microbiol  2021; 6(9): 1188-98.
 [http://dx.doi.org/10.1038/s41564-021-00954-4] [PMID: 34400835]

[35]
Di Giacomo S, Mercatelli D, Rakhimov A, Giorgi FM. Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K. J Med Virol  2021; 93(9): 5638-43.
 [http://dx.doi.org/10.1002/jmv.27062] [PMID: 33951211]

[36]
Ahmad L. Implication of SARS-CoV-2 immune escape spike variants on secondary and vaccine breakthrough infections. Front Immunol  2021; 12: 742167.
 [http://dx.doi.org/10.3389/fimmu.2021.742167] [PMID: 34804022]

[37]
Benvenuto D, Angeletti S, Giovanetti M, et al. Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy. J Infect  2020; 81(1): e24-7.
 [http://dx.doi.org/10.1016/j.jinf.2020.03.058] [PMID: 32283146]

[38]
Spouge JL. A comprehensive estimation of country-level basic reproduction numbers R0 for COVID-19: Regime regression can automati-cally estimate the end of the exponential phase in epidemic data. PLoS One  2021; 16(7): e0254145.
 [http://dx.doi.org/10.1371/journal.pone.0254145] [PMID: 34255772]

[39]
Mukherjee S, Ray SK. The newfangled upsurge of Double mutant SARS-CoV-2 virus in a 2021-Current scenario and inspecting ahead. Recent Adv Anti-Infective Drug Discov  2021; 16(3): 175-8.
 [http://dx.doi.org/10.2174/2772434416666211124150255] [PMID: 34819015]

[40]
Gagne M, et al. mRNA-1273 or mRNA-omicron boost in vaccinated macaques elicits comparable b cell expansion, neutralizing antibodies and protection against omicron. bioRxiv 2022.
 [http://dx.doi.org/10.1101/2022.02.03.479037]

[41]
Jiang Y, Wu Q, Song P, You C. The variation of SARS-CoV-2 and advanced research on current vaccines. Front Med (Lausanne)  2022; 8: 806641.
 [http://dx.doi.org/10.3389/fmed.2021.806641] [PMID: 35118097]

[42]
Hirabara SM, Serdan TDA, Gorjao R, et al. SARS-COV-2 variants: Differences and potential of immune evasion. Front Cell Infect Microbiol  2022; 11: 781429.
 [http://dx.doi.org/10.3389/fcimb.2021.781429] [PMID: 35118007]

[43]
Abd-Elsalam S, Noor RA, Badawi R, et al. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized con-trolled study. J Med Virol  2021; 93(10): 5833-8.
 [http://dx.doi.org/10.1002/jmv.27122] [PMID: 34076901]

[44]
El-Bendary M, Abd-Elsalam S, Elbaz T, et al. Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: A multicenter Egyptian study. Expert Rev Anti Infect Ther  2022; 20(2): 291-5.
 [http://dx.doi.org/10.1080/14787210.2021.1950532] [PMID: 34225541]

[45]
Vallejos J, Zoni R, Bangher M, et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a random-ized, double-blind, placebo-controlled trial. BMC Infect Dis  2021; 21(1): 635.
 [http://dx.doi.org/10.1186/s12879-021-06348-5] [PMID: 34215210]

[46]
Dabbous HM, Abd-Elsalam S, El-Sayed MH, et al. Efficacy of favipiravir in COVID-19 treatment: A multi-center randomized study. Arch Virol  2021; 166(3): 949-54.
 [http://dx.doi.org/10.1007/s00705-021-04956-9] [PMID: 33492523]

[47]
Abd-Elsalam S, Soliman S, Esmail ES, et al. Do zinc supplements enhance the clinical efficacy of hydroxychloroquine?: A randomized, multicenter trial. Biol Trace Elem Res  2021; 199(10): 3642-6.
 [http://dx.doi.org/10.1007/s12011-020-02512-1] [PMID: 33247380]

[48]
Mohamed AA, Mohamed N, Mohamoud S, et al. SARS-CoV-2: The path of prevention and control. Infect Disord Drug Targets  2021; 21(3): 358-62.
 [http://dx.doi.org/10.2174/1871526520666200520112848] [PMID: 32433010]

[49]
Abu-Raddad LJ, Chemaitelly H, Bertollini R.  Severity of SARSCoV- 2 reinfections as compared with primary infections. NEJM 2021. Available from: https://www.nejm.org/doi/full/10.1056/ NEJMc2108120

[50]
 European centre for disease prevention and control (ECDC). Guidance for representative and targeted genomic SARS-CoV-2 monitoring. 2021. Available from: https://www.ecdc.europa.eu/en/ publications-data/guidance-representative-and-targeted-genomic-sarscov- 2-monitoring

[51]
Karim F, Gazy I, Cele S, et al. COMMIT-KZN Team. HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave. eLife  2021; 10: e67397.
 [http://dx.doi.org/10.7554/eLife.67397] [PMID: 34608862]

[52]
Nachega JB, Sam-Agudu NA, Masekela R, et al. Addressing challenges to rolling out COVID-19 vaccines in African countries. Lancet Glob Health  2021; 9(6): e746-8.
 [http://dx.doi.org/10.1016/S2214-109X(21)00097-8] [PMID: 33713633]

[53]
Nachega JB, Kapata N, Sam-Agudu NA, Decloedt EH, Katoto PDMC. Minimizing the impact of the triple burden of COVID-19,
tuberculosis and HIV on health services in sub-Saharan Africa. Int J
Infect Dis 2021; S1201-9712(21): 00256-253.

Rights & Permissions Print Cite

Article Metrics

20

3

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1871526522666220422110415	Print ISSN 1871-5265
Publisher Name Bentham Science Publisher	Online ISSN 2212-3989

Infectious Disorders - Drug Targets

The Emergence of Omicron SARS-CoV-2 Variant (B.1.1.529): The Latest Episode in the COVID-19 Pandemic with a Global Riposte

Abstract

Graphical Abstract

Related Journals

Related Books

Related Articles